Next year, the company will pursue regulatory clearance for its wearable device, CardioTag. The company’s first application using artificial intelligence to improve the management of congestive heart failure, according to a Dec. 8 Cardiosense news release.
The financing round was co-led by Broadview Ventures and Hatteras Venture Partners. Cardiosense plans to use the financing to expand its team, accelerate product development and fund a heart failure study.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
